What are the different types of cerebral aneurysms and their treatment options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Types of Cerebral Aneurysms and Their Treatment

Classification of Cerebral Aneurysms

Cerebral aneurysms are classified into two major morphological categories: saccular (berry) aneurysms and fusiform aneurysms, with additional rare subtypes including dissecting, mycotic, marantic, and blister aneurysms. 1, 2

Saccular (Berry) Aneurysms

  • Most common type, accounting for the vast majority of intracranial aneurysms 1
  • Can be further subdivided based on relationship to branch vessels:
    • Aneurysms not associated with branch vessels (least common) 2
    • Side-branch aneurysms (associated with a side-branch vessel) 2
    • Bifurcation aneurysms (located at vessel bifurcations, most common subtype) 2

Fusiform Aneurysms

  • Characterized by circumferential dilation of the vessel wall 1, 2
  • Subdivided into:
    • Simple fusiform (no branch vessels involved) 2
    • Complex fusiform (one or more side branches involved) 2

Rare Aneurysm Types

  • Dissecting aneurysms: Result from intimal tear with blood dissecting into vessel wall 1
  • Mycotic (infectious) aneurysms: Caused by septic emboli, typically located distally and far from typical congenital aneurysm sites 1, 3
  • Blister aneurysms: Small, fragile lesions with thin walls 1
  • Marantic aneurysms: Associated with malignancy 1

Treatment Approach by Rupture Status

Ruptured Aneurysms (Aneurysmal Subarachnoid Hemorrhage)

For patients with ruptured saccular aneurysms amenable to both techniques, endovascular coiling is preferred over surgical clipping for good-grade anterior circulation aneurysms to improve functional outcomes at 1 year. 4

Immediate Management Priorities

  • Secure the aneurysm within 24 hours when feasible to prevent catastrophic rebleeding, which occurs in 2.4-10.8% of unsecured aneurysms with 80% mortality 4
  • Administer nimodipine 60 mg orally every 4 hours for 21 consecutive days starting within 96 hours of hemorrhage onset, regardless of Hunt-Hess grade, to reduce ischemic deficits 4, 5
  • Control blood pressure with titratable agents to balance rebleeding risk against cerebral perfusion 4

Treatment Selection Algorithm

  • For good-grade aSAH with anterior circulation aneurysms: Choose endovascular coiling over clipping 4
  • For middle cerebral artery aneurysms: Microsurgical clipping demonstrates advantage with current technology 6
  • For basilar apex and vertebrobasilar confluence aneurysms: Endovascular repair shows advantage 6
  • Treatment must be performed at high-volume centers (>35 cases/year) as low-volume hospitals (<10 cases/year) have inferior outcomes 4

Procedural Efficacy Data

  • Surgical clipping rerupture rate: 0.1-0.3% annually after complete occlusion 6
  • Endovascular coiling rerupture rate: 0.9% annually across all locations 6
  • Degree of occlusion is the strongest predictor of rerupture: Complete occlusion carries 1.1% risk, 91-99% occlusion carries 2.9% risk, 70-90% occlusion carries 5.9% risk, and <70% occlusion carries 17.6% risk 7

Unruptured Intracranial Aneurysms (UIAs)

Treatment decisions for unruptured aneurysms must weigh size, location, patient age, and rupture risk against procedural morbidity, with observation being reasonable for small (<5mm) asymptomatic aneurysms in older patients. 6

Size-Based Treatment Algorithm

Aneurysms <5mm:

  • Manage conservatively in virtually all cases 6
  • Observation is reasonable, particularly in patients >65 years with low rupture risk 6

Aneurysms 5-10mm:

  • Seriously consider treatment in patients <60 years of age 6
  • In patients >65 years with medical comorbidities, observation is reasonable 6

Aneurysms >10mm:

  • Treat in nearly all patients <70 years of age 6
  • Large aneurysms carry approximately 1% annual rupture risk for 7-10mm lesions 6

Symptomatic Unruptured Aneurysms

With rare exceptions, all symptomatic unruptured aneurysms should be treated regardless of size, as symptoms indicate mass effect or hemodynamic compromise 6, 8

Treatment Modality Selection

Microsurgical clipping advantages:

  • More durable protection against aneurysm regrowth and recurrence 6
  • Preferred for middle cerebral artery aneurysms 6
  • Should be first treatment choice in low-risk cases 6

Endovascular coiling advantages:

  • Superior procedural morbidity/mortality profile (2.6% permanent complications vs 7-15% for surgery in patients >60 years) 6, 8
  • Lower in-hospital mortality (0.4-0.5% vs 2.3-3.5% for surgery) 8
  • Preferred for basilar apex and vertebrobasilar aneurysms 6
  • Greater benefit in older patients (>60 years) as recurrence risk becomes less concerning over remaining lifespan 6

Emerging Technologies

  • Flow-diverting stents and stent-assisted coiling may be considered in carefully selected cases 6
  • Strict adherence to FDA indications is mandatory until long-term safety/efficacy data demonstrate superiority over existing technologies 6
  • For ruptured saccular aneurysms amenable to coiling or clipping, stents or flow diverters should NOT be used due to higher complication risk 9

Special Aneurysm Types: Treatment Considerations

Mycotic (Infectious) Aneurysms

  • Early targeted antimicrobial therapy is crucial and takes priority over aneurysm treatment 3
  • Aneurysm elimination should be evaluated carefully as these lesions are typically fusiform, fragile, and located distally 3
  • Blood cultures and evaluation for endocarditis are mandatory 3
  • Reconstructive procedures often fail due to fragile aneurysm walls; parent vessel sacrifice may be necessary 3

Giant Aneurysms

In patients where both treatment and natural history carry high risks (such as giant aneurysms), nonoperative management is typically elected 6


Post-Treatment Management

Immediate Post-Procedure Assessment

  • Obtain immediate cerebrovascular imaging after any repair to identify remnants or incomplete occlusion requiring retreatment 4, 9
  • Document neurological examination within 24 hours to identify procedural complications 8

Long-Term Follow-Up

  • Increase imaging frequency for incompletely obliterated aneurysms 6, 9
  • Regular surveillance is necessary to detect recurrence and de novo aneurysm formation 6, 9
  • Assessment of cognitive outcome in addition to standard measures is reasonable after any treatment 6, 9

Antiplatelet Therapy (for endovascular procedures)

  • Dual antiplatelet therapy (aspirin 81-325mg plus clopidogrel 75mg daily) must be administered before and for minimum 30 days after endovascular procedures 8

Critical Pitfalls to Avoid

  • Never use thrombolytics or anticoagulation in acute aSAH due to catastrophic rebleeding risk 4
  • Do not treat at low-volume centers (<20 cases annually); transfer to high-volume centers is strongly indicated 6, 4
  • Incomplete aneurysm occlusion dramatically increases rerupture risk; complete occlusion should be the goal whenever technically feasible 7
  • Do not assume complete occlusion eliminates all risk; long-term follow-up imaging remains necessary 6, 9

References

Research

Cerebral aneurysm classification based on angioarchitecture.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2011

Guideline

Management of Stroke Following Cerebral Aneurysm Rupture

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Medical Necessity Assessment for Symptomatic Unruptured Aneurysms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Small Anterior Communicating Artery Aneurysms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.